Why the study?
GPVI is a viable antithrombotic target participating in arterial thrombosis while being less involved in hemostasis, prompting review of its interactions with fibrin and fibrinogen and emerging therapeutic developments.
Design
Review
Key result
Glycoprotein VI interacts with fibrin and fibrinogen to promote thrombus growth and stability, presenting a viable antithrombotic target with therapies currently in clinical trials.
Authors
Loading...
Supports ongoing GPVI inhibitor trials in arterial thrombosis; leaves open net clinical benefit versus bleeding risk.
Targeting the GPVI-fibrin(ogen) interaction offers a promising therapeutic strategy to prevent arterial thrombosis while preserving normal hemostasis.
Mangin et al. (2023) conducted a review in Thrombosis. GPVI targeted therapies was evaluated. Glycoprotein VI interacts with fibrin and fibrinogen to promote thrombus growth and stability, presenting a viable antithrombotic target with therapies currently in clinical trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: